Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Airbus Joins Air India A320 Altitude Drop Probe 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
With the world impacted by the pandemic, the goal to bring medical alternatives to market first is now the utmost priority for many pharmaceutical companies. In support of finding these solutions, Samsung Biologics has signed a contract manufacturing agreement with GlaxoSmithKline (GSK) to produce neutralizing antibodies for COVID-19.
In April, GSK invested $250 million in the research of Vir Biotechnology to create a collaborative COVID-19 antibody treatment. With no approved treatment currently on the market, the collaborative efforts are looking at antibodies of recovered patients to see how they can help new patients recover. This is different than plasma therapy with antibodies because Vir is selecting key antibodies from the plasma to establish a process easier to administer on a large scale, making it more efficient to reach a global market. Samsung Biologics looks to help speed up that solution by offering its manufacturing service to GSK
The boost of outsourcing contracts that Samsung Biologics has gained during the COVID-19 pandemic can be largely chalked up to their unwavering drive towards quality and innovation. The company prides itself on offering a wide range of services, so clients need fewer jumps in their production and testing process.
Samsung Biologics also recently announced plans for a fourth plant expansion—estimated to invest around 2 billion USD—which will maximize operational efficiency, scale up its development and manufacturing capabilities, and through a second bio complex, foster biotech companies with an Open Innovation Center and global R&D facility.
In a time where resilient supply chains and pharmaceutical solutions are desperately needed, Samsung Biologics is filling the gap. Clients can use the large capacity and proven regulatory track record to place their products in good hands for a faster-to-market turnaround. The company also works to cut excess production time and create a development process that works best for the client. The goal is to get quality products into the hands of the patients that desperately need them.
This article does not necessarily reflect the opinions of the editors or management of EconoTimes
